<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>1475-2867-4-S1-S6</ui>
   <ji>1475-2867</ji>
   <fm>
      <dochead>Oral presentation</dochead>
      <bibl>
         <title>
            <p>MMP-7 inhibits CTL &#8211; tumor cell interaction</p>
         </title>
         <aug>
            <au id="A1" ca="yes">
               <snm>Gregor</snm>
               <fnm>S</fnm>
               <insr iid="I1"/>
               <email>spgregor@web.de </email>
            </au>
            <au id="A2">
               <snm>Alla</snm>
               <fnm>V</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A3">
               <snm>Kuball</snm>
               <fnm>J</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A4">
               <snm>Theobald</snm>
               <fnm>M</fnm>
               <insr iid="I2"/>
            </au>
            <au id="A5">
               <snm>Galle</snm>
               <fnm>PR</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A6">
               <snm>Strand</snm>
               <fnm>D</fnm>
               <insr iid="I1"/>
            </au>
            <au id="A7">
               <snm>Strand</snm>
               <fnm>S</fnm>
               <insr iid="I1"/>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>I. Medizinische Klinik und Poliklinik</p>
            </ins>
            <ins id="I2">
               <p>III. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universit&#228;t Mainz, Germany</p>
            </ins>
         </insg>
         <source>Cancer Cell International</source>
         <supplement>
            <title>
               <p>Association for Immunotherapy of Cancer: Cancer Immunotherapy &#8211; 2<sup>nd </sup>Annual Meeting</p>
            </title>
            <note>Meeting abstracts</note>
         </supplement>
         <conference>
            <title>
               <p>Association for Immunotherapy of Cancer: Cancer Immunotherapy &#8211; 2<sup>nd </sup>Annual Meeting</p>
            </title>
            <location>Mainz, Germany</location>
            <date-range>6&#8211;7 May 2004</date-range>
            <url>http://www.c-imt.org</url>
         </conference>
         <issn>1475-2867</issn>
         <pubdate>2004</pubdate>
         <volume>4</volume>
         <issue>Suppl 1</issue>
         <fpage>S6</fpage>
         <url>http://www.cancerci.com/content/4/S1/S6</url>
         <xrefbib>
            <pubid idtype="doi">10.1186/1475-2867-4-S1-S6</pubid>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>28</day>
               <month>4</month>
               <year>2004</year>
            </date>
         </rec>
         <pub>
            <date>
               <day>1</day>
               <month>7</month>
               <year>2004</year>
            </date>
         </pub>
      </history>
   </fm>
   <bdy>
      <sec>
         <st>
            <p/>
         </st>
         <p>MMP-7, the smallest member of the MMP-family, is a zinc-dependent metalloproteinase and is overexpressed in colon cancer and many other human cancers. Along with its prometastatic function, a fundamental role for MMP-7 has also been established in early tumor development, but the mechanism by which MMP-7 contributes to this, is still unknown.</p>
         <p>Tumor specific cytotoxic T cells (CTLs) play a critical role in the control of tumor growth. They can induce apoptosis by CD95 as well as perforin/granzyme mediated pathways. Loss of CD95 may contribute to apoptosis resistance and immune escape of tumor cells leading to successful tumor outgrowth.</p>
         <p>In our project we analyzed MMP-7 for its influence on CD95 mediated apoptosis and the cytolytic effector functions of CTLs. Furthermore we investigated the influence of MMP-7 cleavage activity on the adhesion and deadhesion of peptide specific CTL's to tumor targets.</p>
         <p>In a cleavage assay with recombinant CD95 protein, we could show that MMP-7, cleaved approximately 2&#8211;3 kDa from the extracellular N-terminal end of CD95. In coculture experiments with <sup>51</sup>Cr-labeled HepG2-cells, we found a significant decrease of cytotoxic action of peptide specific CTLs in the presence of MMP-7. In addition MMP-7 leads to a higher adhesion of CTLs and inhibits their deadhesion from HepG2 cells. Considering that CTL's are serial killers, alteration in adhesion/deadhesion functions can be detrimental for tumor specific CTL killing.</p>
         <p>Our results show, that MMP-7 can contribute to the apoptosis resistance of tumor cells by different mechanisms. These activities may explain the contribution of MMP-7 to early tumor growth.</p>
      </sec>
   </bdy>
</art>
